北京市天元律师事务所 关于创业慧康科技股份有限公司 作废处理部分限制性股票的 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于创业慧康科技股份有限公司 本所律师特作如下声明： 1、本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见出具 之日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚 实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、 完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大 遗漏，并承担相应法律责任。 2、公司已保证其向本所提供的与本法律意见相关的信息、文件或资料均为 真实、准确、完整、有效，不存在虚假记载、误导性陈述或重大遗漏；文件资料 为副本、复印件的，内容均与正本或原件相符；所有文件的签署人均具有完全民 事行为能力，并且其签署行为已获得恰当、有效的授权；所有文件或资料上的签 字和印章均为真实。 作废处理部分限制性股票的 法律意见 京天股字（2022）第 ...

创业慧康科技股份有限公司 公司相关治理制度修订对照表 创业慧康科技股份有限公司于 2024 年 12 月 25 日召开了第八届董事会第十 二次会议，根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所上市 公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股份》《上 市公司独立董事管理办法》等法律法规及相关规范性文件的规定，对《董事、监 事和高级管理人员持有和买卖本公司股票管理制度（2024 年 6 月）》进行修订。 修订的条款及具体内容如下： | 修订前 | | 修订后 | | --- | --- | --- | | 第五章 公司董事、监 | 第二十一条 | 删除。 | | 事、高级管理人员在减持数量过半或减 | | | | 持时间过半时，应书面告知公司董事 | | | | 会，公司需披露减持进展情况。 | | | 创业慧康科技股份有限公司 董事会 2024 年 12 月 26 日 一、董事、监事和高级管理人员持有和买卖本公司股票管理制度（2024 年 12 月） ...

创业慧康科技股份有限公司 舆情管理制度 二○二四年十二月 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受较大损失，已经或可能造成公司股票及其衍生品交 易价格异常波动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 舆情管理制度 第一章 总则 第一条 为提高创业慧康科技股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司形 象、商业信誉、股票及其衍生品交易价格及日常正常生产经营可能造成的影响， 切实保护投资者及公司的合法权益，根据相关法律、法规和规范性文件的规定及 《公司章程》，结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第四条 公司舆情应对坚持"统一指挥、快速反应、实事求是、科学应对、 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-044 创业慧康科技股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届董事 会第十二次会议的通知于 2024 年 12 月 19 日以邮件、传真等方式向各位董事发 出，并于 2024 年 12 月 25 日在公司三楼会议室以现场结合通讯的方式召开。会 议应到董事 11 名，实到董事 11 名，公司部分监事、高级管理人员列席了会议。 会议的召开及表决符合《中华人民共和国公司法》《创业慧康科技股份有限公司 章程》等有关规定。 此次会议由董事长张吕峥先生主持，参会董事认真审议后，依照有关规定通 过以下决议： 一、审议通过了《关于修订<董事、监事和高级管理人员持有和买卖本公司 股票管理制度（2024 年 6 月）>的议案》 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的《公司相关治理制度修订对照表》及《董事、监事和 高级管理人员持有和买卖本公司股票 ...

创业慧康科技股份有限公司 董事、监事和高级管理人员持有和买卖 本公司股票管理制度 二○二四年十二月 第一章 总 则 第一条 为加强对创业慧康科技股份有限公司（以下简称"公司"或"本公 司"）董事、监事和高级管理人员所持本公司股份及其变动的管理，根据《公司 法》《证券法》和中国证券监督管理委员会（以下简称"中国证监会"）《上市 公司董事、监事和高级管理人员所持本公司股份及其变动管理规则》以及深圳证 券交易所（以下简称"深交所"）《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股份》等规定，特制定本制度。 第二条 公司董事、监事和高级管理人员所持本公司股份，是指登记在其名 下和利用他人账户持有的所有本公司股份。 公司董事、监事和高级管理人员从事融资融券交易的，其所持本公司股份还 包括记载在其信用账户内的本公司股份。 第三条 公司董事、监事和高级管理人员及本制度第七条规定的自然人、法 人或其他组织持有及买卖本公司股份的，应当遵守本制度的有关规定进行股份买 卖行为。 公司及董事、监事和高级管理人员在买卖本公司股票及其衍生品种前，应知 悉《公司法》《证券法》等法律、法规、规范性文件 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-043 创业慧康科技股份有限公司 关于持股 5%以上股东减持股份计划的预披露公告 持股 5%以上股东葛航先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"、"本公司"）于近日收到 持股 5%以上股东葛航先生出具的《关于股份减持计划的告知函》，现将相关事 项公告如下： 一、股东的基本情况 1、股东的名称：葛航 2、股东持股情况：截至本公告日，葛航先生持有本公司 220,519,182 股，占 本公司总股本比例 14.24%，占剔除公司回购专用账户股份后总股本比例 14.28%。 二、本次减持计划的主要内容 1、减持原因：偿还债务及利息，降低质押融资风险。 2、股份来源：公司首次公开发行前已发行的股份、发行股份购买资产非公 开发行方式获得的股份（包括资本公积金转增股本部分）。 3、减持数量：以集中竞价方式减持不超过 15,444,264 股（含），且任意连 续 90 日内减持股份的总数不超过公司股份总数的 1.00%；若此期间，公司有送 股、资本公积金转增股份变动事项，该 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price reflecting a potential upside of over 20% within the next six months [7][15]. Core Insights - The company is steadily advancing its cloud transformation strategy, leveraging data services and AI innovations to enhance its offerings [1][2]. - In Q3 2024, the company reported a revenue of 442 million yuan, a year-on-year decrease of 2.35%, and a net profit attributable to the parent company of 25 million yuan, down 62.33% year-on-year [1]. - The healthcare sector remains robust, with revenue reaching 1.12 billion yuan in the first three quarters of 2024, accounting for over 95.89% of total revenue, marking a year-on-year growth of 6.19% [2][4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved total revenue of 1.169 billion yuan, a slight increase of 1.01% year-on-year, while net profit attributable to the parent company was 53 million yuan, down 42.27% year-on-year [1]. - The overall expense ratio for the first three quarters was 35.48%, a decrease of 2.96 percentage points year-on-year, with sales, management, and R&D expense ratios at 7.35%, 14.89%, and 15.87%, respectively [1]. - The company expects net profits for 2024-2026 to be 150 million, 216 million, and 305 million yuan, respectively, with corresponding P/E ratios of 60, 42, and 30 [3]. Strategic Developments - The company has signed 20 new contracts worth over 10 million yuan each in the healthcare sector and has assisted seven hospitals in passing electronic medical record evaluations [2]. - The new generation product HI-HIS is being actively promoted, with 71 ongoing projects, over 70% of which are in tertiary hospitals [2]. - The company has established a partnership with Huawei for deep collaboration on the HarmonyOS version of its healthcare app, which integrates health services in the Tongxiang area [3][5]. Market Position and Valuation - The company is recognized as one of the first information technology vendors in the healthcare sector to receive native development certification from Kunpeng [3]. - The financial projections indicate a recovery in the healthcare IT demand, with expected revenue growth rates of 11.20%, 10.60%, and 10.30% for 2024, 2025, and 2026, respectively [11].

Investment Rating - The report maintains a "Buy" rating for Chuangxin Huikang (300451 SZ) with a target price of 5 47 RMB per share [4] Core Views - Chuangxin Huikang's 2024 Q1-3 performance was under pressure due to declining gross margins and increased impairment losses The company reported revenue of 1 17 billion RMB, a 1 0% YoY increase, while net profit attributable to shareholders dropped 42 3% YoY to 52 75 million RMB [1][7] - The gross margin for 2024 Q1-3 was 50 1%, down 2 6 percentage points YoY, with Q3 gross margin at 43 45%, a 10 52 percentage point decline YoY [1][7] - The company recognized impairment losses of 43 66 million RMB in Q3 2024, a 25 0% YoY increase, mainly due to higher provisions for accounts receivable and contract assets [1][7] - The Hi-HIS product is being actively promoted, with 71 ongoing projects, over 70% of which are in tertiary hospitals The company's AI product "Medical Copilot" has received compatibility certification from Huawei's Ascend AI framework [1][13] Financial Performance - 2024 Q1-3 revenue was 1 17 billion RMB, up 1 0% YoY, while net profit attributable to shareholders was 52 75 million RMB, down 42 3% YoY [7] - Q3 2024 revenue was 440 million RMB, down 2 4% YoY, with net profit attributable to shareholders dropping 62 3% YoY to 25 38 million RMB [8] - Operating cash flow for 2024 Q1-3 was -200 million RMB, compared to -170 million RMB in the same period last year [8] - Accounts receivable increased 19 0% to 1 88 billion RMB as of September 2024, while contract liabilities decreased 3 9% to 151 million RMB [8] Product and Market Development - The Hi-HIS product is being promoted in 71 projects, with over 70% in tertiary hospitals The company expects gross margins to improve as the product matures [1][13] - The company's BSoftGPT model has been approved by the National Internet Information Office, and its AI product "Medical Copilot" has received Huawei Ascend AI framework certification [1][13] - Chuangxin Huikang is the first core medical system supplier to receive Huawei's Kunpeng native development certification and has collaborated with Huawei's HarmonyOS team to develop a native version of the Health Tongxiang app [1][13] Financial Forecasts - Revenue for 2024-2026 is projected to be 1 70 billion, 1 85 billion, and 2 00 billion RMB, respectively, with net profit attributable to shareholders expected to be 100 million, 270 million, and 330 million RMB [2][18] - EPS for 2024-2026 is forecasted at 0 06, 0 17, and 0 22 RMB per share, respectively [2][18] - The company's 2025 PE ratio is estimated at 32x, with a target price of 5 47 RMB per share [2][18] Industry and Market Position - Chuangxin Huikang is a leading player in the medical IT industry, with a strong focus on AI and healthcare information systems [1][13] - The company has established partnerships with major players like Huawei, positioning itself as a key supplier in the healthcare information technology sector [1][13]

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 5.20 and a sector rating of "Outperform" compared to the market [1]. Core Views - The company is expected to benefit from the recent government policy aimed at debt reduction, which is anticipated to improve its financial statements. The policy is expected to alleviate the debt burden on local governments, enhancing the company's cash flow and receivables collection [3]. - The acceleration of public data resource marketization is expected to benefit the company, as it provides various data services across multiple fields, including clinical research and insurance underwriting [3]. - The company has established multiple collaborations with Huawei in the healthcare information sector, which is expected to enhance its technological capabilities and service offerings [3]. - The earnings per share (EPS) estimates for 2024-2026 are projected to be RMB 0.14, RMB 0.20, and RMB 0.26, respectively, with corresponding price-to-earnings (PE) ratios of 36X, 26X, and 20X [3]. Financial Summary - The company reported a revenue of RMB 1.17 billion for the first three quarters of 2024, reflecting a year-on-year growth of 1.0%. However, the net profit attributable to the parent company decreased by 42.3% to RMB 52.75 million [3]. - The projected revenue for the years 2024 to 2026 is expected to grow from RMB 1.80 billion to RMB 2.48 billion, with growth rates of 11.4%, 16.7%, and 17.9%, respectively [4]. - The net profit for the same period is projected to increase significantly from RMB 219 million in 2024 to RMB 395 million in 2026, indicating a growth rate of 498.0% in 2024 [4][6]. - The company's EBITDA is expected to rise from RMB 284 million in 2024 to RMB 449 million in 2026, reflecting a strong growth trajectory [4][6].